Arthur J. Higgins, a director at Zimmer Biomet Holdings, Inc., has reported the acquisition of 306.066 phantom stock units as part of his compensation plan. This transaction, filed on October 2, 2026, is significant as it highlights the ongoing trend of aligning executive compensation with company performance in the biological products sector.
Background
Higgins is associated with Zimmer Biomet Holdings, Inc., a company classified under SIC code 2836, which focuses on biological products (no diagnostic substances). The company is publicly traded and operates primarily in the orthopedic, prosthetic, and surgical appliances and supplies market. Recent filings indicate that Higgins has been active in reporting stock transactions, with the latest filing dated October 2, 2026.
What the Filing Says
The SEC filing reveals that Higgins acquired the phantom stock units at a conversion price of $89.85 per unit. The transaction date is noted as September 30, 2026. Following this acquisition, Higgins now holds a total of 38,077.496 shares, which includes additional phantom stock units accrued under the company's Deferred Compensation Plan for Non-Employee Directors.
Impact
This acquisition may influence various stakeholders, including shareholders and potential investors, as it reflects Higgins' commitment to the company’s future. The biological products industry, where Zimmer Biomet operates, often sees such compensation structures as a means to ensure that executives are motivated to enhance shareholder value.
What's Next
The filing does not say what happens next.